Table 2.
Overall response rates for single agents in advanced gastric cancer (Japanese phase II studies).
| Drug | No. pts. | Response rate | Author |
|---|---|---|---|
| UFT | 188 | 27.7% | Ota15 |
| 5′ -DFUR | 140 | 14.3% | Nitani17 |
| Epi-ADM | 31 | 16.1% | Sakata 18 |
| Cisplatin | 68 | 19.1% | Ishibiki19 |
| S-1 | 51 | 49.0% | Sakata23 |
| 50 | 40.0% | Koizumi24 | |
| Capecitabine | 31 | 19.4% | Koizumi28 |
| 55 | 25.5% | Sakamoto29 | |
| Irniotecan | 60 | 23.3% | Futatsuki 30 |
| Docetaxel | 59 | 23.7% | Taguchi31 |
| 59 | 23.7% | Mai32 | |
| Paclitaxel | 32 | 28.1% | Yamaguchi33 |
| 60 | 23.3% | Yamada34 | |
Abbreviations: Epi = epirubicin; ADM = doxorubicin (Adriamycin).